

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Current overview and treatment of mantle cell... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/7-1136/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/7-1136" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Current overview and treatment of mantle cell lymphoma" />
    
            <meta name="og:title" content="F1000Research Article: Current overview and treatment of mantle cell lymphoma.">
            <meta name="og:description" content="Read the latest article version by Michael Schieber, Leo I. Gordon, Reem Karmali, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="15360">
            <meta name="article-id" content="14122">
            <meta name="dc.title" content="Current overview and treatment of mantle cell lymphoma">
            <meta name="dc.description" content="Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma with historically poor long-term survival compared with other B-cell malignancies. Treatment strategies for this disease are variable and dependent on symptoms and patient fitness. Despite recent advances, MCL remains incurable and patients with high-risk disease have particularly poor outcomes. This review focuses on recent developments that enhance our understanding of the biology of MCL and new treatment approaches that have led to substantial improvements in clinical outcomes. We will outline induction immuno-chemotherapy and maintenance strategies in transplant-eligible patients. In addition, effective strategies for patients unfit for intensive induction will be discussed, with a particular focus on novel molecular therapies with activity in MCL. Lastly, a number of ongoing clinical trials will be presented; the data from these trials are anticipated to redefine standards of care in the near future.">
            <meta name="dc.subject" content="Mantle Cell Lymphoma, Management, Treatment, Diagnosis, Clinical trials">
            <meta name="dc.creator" content="Schieber, Michael">
            <meta name="dc.creator" content="Gordon, Leo I.">
            <meta name="dc.creator" content="Karmali, Reem">
            <meta name="dc.date" content="2018/07/25">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.14122.1">
            <meta name="dc.source" content="F1000Research 2018 7:1136">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Mantle Cell Lymphoma">
            <meta name="prism.keyword" content="Management">
            <meta name="prism.keyword" content="Treatment">
            <meta name="prism.keyword" content="Diagnosis">
            <meta name="prism.keyword" content="Clinical trials">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2018/07/25">
            <meta name="prism.volume" content="7">
            <meta name="prism.number" content="1136">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.14122.1">
            <meta name="prism.url" content="https://f1000research.com/articles/7-1136">
            <meta name="citation_title" content="Current overview and treatment of mantle cell lymphoma">
            <meta name="citation_abstract" content="Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma with historically poor long-term survival compared with other B-cell malignancies. Treatment strategies for this disease are variable and dependent on symptoms and patient fitness. Despite recent advances, MCL remains incurable and patients with high-risk disease have particularly poor outcomes. This review focuses on recent developments that enhance our understanding of the biology of MCL and new treatment approaches that have led to substantial improvements in clinical outcomes. We will outline induction immuno-chemotherapy and maintenance strategies in transplant-eligible patients. In addition, effective strategies for patients unfit for intensive induction will be discussed, with a particular focus on novel molecular therapies with activity in MCL. Lastly, a number of ongoing clinical trials will be presented; the data from these trials are anticipated to redefine standards of care in the near future.">
            <meta name="citation_description" content="Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma with historically poor long-term survival compared with other B-cell malignancies. Treatment strategies for this disease are variable and dependent on symptoms and patient fitness. Despite recent advances, MCL remains incurable and patients with high-risk disease have particularly poor outcomes. This review focuses on recent developments that enhance our understanding of the biology of MCL and new treatment approaches that have led to substantial improvements in clinical outcomes. We will outline induction immuno-chemotherapy and maintenance strategies in transplant-eligible patients. In addition, effective strategies for patients unfit for intensive induction will be discussed, with a particular focus on novel molecular therapies with activity in MCL. Lastly, a number of ongoing clinical trials will be presented; the data from these trials are anticipated to redefine standards of care in the near future.">
            <meta name="citation_keywords" content="Mantle Cell Lymphoma, Management, Treatment, Diagnosis, Clinical trials">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Michael Schieber">
            <meta name="citation_author_institution" content="Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA">
            <meta name="citation_author" content="Leo I. Gordon">
            <meta name="citation_author_institution" content="Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA">
            <meta name="citation_author" content="Reem Karmali">
            <meta name="citation_author_institution" content="Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA">
            <meta name="citation_publication_date" content="2018/07/25">
            <meta name="citation_volume" content="7">
            <meta name="citation_publication_number" content="1136">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.14122.1">
            <meta name="citation_firstpage" content="1136">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/7-1136/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/7-1136.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=15360 /> <input type=hidden id=articleId name=articleId value=14122 /> <input type=hidden id=xmlUrl value="/articles/7-1136/v1/xml"/> <input type=hidden id=xmlFileName value="-7-1136-v1.xml"> <input type=hidden id=article_uuid value=335ffc0e-e637-4313-8181-fc476dba01bf /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Current overview and treatment of mantle cell lymphoma"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.14122.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.14122.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/7-1136"
  },
  "headline": "Current overview and treatment of mantle cell lymphoma",
  "datePublished": "2018-07-25T15:41:10",
  "dateModified": "2018-07-25T15:41:10",
  "author": [
    {
      "@type": "Person",
      "name": "Michael Schieber"
    },    {
      "@type": "Person",
      "name": "Leo I. Gordon"
    },    {
      "@type": "Person",
      "name": "Reem Karmali"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma with historically poor long-term survival compared with other B-cell malignancies. Treatment strategies for this disease are variable and dependent on symptoms and patient fitness. Despite recent advances, MCL remains incurable and patients with high-risk disease have particularly poor outcomes. This review focuses on recent developments that enhance our understanding of the biology of MCL and new treatment approaches that have led to substantial improvements in clinical outcomes. We will outline induction immuno-chemotherapy and maintenance strategies in transplant-eligible patients. In addition, effective strategies for patients unfit for intensive induction will be discussed, with a particular focus on novel molecular therapies with activity in MCL. Lastly, a number of ongoing clinical trials will be presented; the data from these trials are anticipated to redefine standards of care in the near future."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/7-1136/v1",
            "name": "Current overview and treatment of mantle cell lymphoma"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Current overview and treatment of mantle cell lymphoma </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=15360 data-id=14122 data-downloads="" data-views="" data-scholar="10.12688/f1000research.14122.1" data-recommended="" data-doi="10.12688/f1000research.14122.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/7-1136/v1/pdf?article_uuid=335ffc0e-e637-4313-8181-fc476dba01bf" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-14122-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-14122-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-14122-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Schieber M, Gordon LI and Karmali R. Current overview and treatment of mantle cell lymphoma [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1136 (<a class=new-orange href="https://doi.org/10.12688/f1000research.14122.1" target=_blank>https://doi.org/10.12688/f1000research.14122.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-14122-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=14122 id=track-article-signin-14122 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/14122?target=/articles/7-1136/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=15360 /> <input name=articleId type=hidden value=14122 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Current overview and treatment of mantle cell lymphoma</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Michael Schieber<a href="https://orcid.org/0000-0001-9994-8579" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-9994-8579</div>,&nbsp;</span><span class=""><a href="mailto:l-gordon@northwestern.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Leo I. Gordon</span></a>,&nbsp;</span><span class=""><a href="mailto:reem.karmali@northwestern.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Reem Karmali</span></a></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Michael Schieber<a href="http://orcid.org/0000-0001-9994-8579" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-9994-8579</div>,&nbsp;</span><span class=""><a href="mailto:l-gordon@northwestern.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Leo I. Gordon</span></a>,&nbsp;</span><span class=""><a href="mailto:reem.karmali@northwestern.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Reem Karmali</span></a></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 25 Jul 2018 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.14122.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA<br/> <p> <div class=margin-bottom> Michael Schieber <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Leo I. Gordon <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Reem Karmali <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=36724-36191></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=36725-36190></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=36714-36189></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma with historically poor long-term survival compared with other B-cell malignancies. Treatment strategies for this disease are variable and dependent on symptoms and patient fitness. Despite recent advances, MCL remains incurable and patients with high-risk disease have particularly poor outcomes. This review focuses on recent developments that enhance our understanding of the biology of MCL and new treatment approaches that have led to substantial improvements in clinical outcomes. We will outline induction immuno-chemotherapy and maintenance strategies in transplant-eligible patients. In addition, effective strategies for patients unfit for intensive induction will be discussed, with a particular focus on novel molecular therapies with activity in MCL. Lastly, a number of ongoing clinical trials will be presented; the data from these trials are anticipated to redefine standards of care in the near future. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Mantle Cell Lymphoma, Management, Treatment, Diagnosis, Clinical trials </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Leo I. Gordon (<a href="mailto:l-gordon@northwestern.edu">l-gordon@northwestern.edu</a>) <br> Reem Karmali (<a href="mailto:reem.karmali@northwestern.edu">reem.karmali@northwestern.edu</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding authors:</b> Leo I. Gordon, Reem Karmali </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2018 Schieber M <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Schieber M, Gordon LI and Karmali R. Current overview and treatment of mantle cell lymphoma [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1136 (<a href="https://doi.org/10.12688/f1000research.14122.1" target=_blank>https://doi.org/10.12688/f1000research.14122.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 25 Jul 2018, <b>7</b>(F1000 Faculty Rev):1136 (<a href="https://doi.org/10.12688/f1000research.14122.1" target=_blank>https://doi.org/10.12688/f1000research.14122.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 25 Jul 2018, <b>7</b>(F1000 Faculty Rev):1136 (<a href="https://doi.org/10.12688/f1000research.14122.1" target=_blank>https://doi.org/10.12688/f1000research.14122.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d35442e180>Introduction</h2><p class="" id=d35442e183>Mantle cell lymphoma (MCL) is an aggressive mature B-cell non-Hodgkin lymphoma (B-NHL) with historically poor long-term survival. Recent progress in our understanding of the biology of MCL has led to substantial improvements in patient outcomes and the development of a number of novel targeted therapies. In this review, the pathogenesis of MCL will be reviewed with a focus on newly defined MCL subtypes that predict response to therapy. We will discuss the major breakthroughs in MCL care in the past 5 years, including recent phase III clinical data that reinforce the use of high-dose cytarabine induction immunochemotherapy in fit patients. There are now data from randomized studies supporting the use of rituximab maintenance in MCL post-autologous stem cell transplant (ASCT). A number of new strategies for the management of patients unfit for ASCT will be reviewed. For those patients who unfortunately experience a relapse of their disease, a number of novel therapies have demonstrated substantial benefit, most notably the Bruton’s tyrosine kinase (BTK) inhibitors ibrutinib and acalabrutinib. Lastly, mechanisms of therapy resistance as well as future directions of treatment will be discussed.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d35442e189>Biology of mantle cell lymphoma</h2><p class="" id=d35442e192>While defined as a mature B-NHL, MCL has a clinical presentation and natural course that often mimic its more aggressive B-NHL counterparts. Patients commonly have lymphadenopathy, splenomegaly, bone marrow involvement, and gastrointestinal infiltration at the time of diagnosis. MCL is classically defined by the t(11;14)(q13;q32) translocation which juxtaposes the <i>CCDN1</i> gene encoding cyclin D1 to the immunoglobulin heavy chain (IgH), resulting in the overexpression of cyclin D1. Alternatively, less-frequent alterations in <i>CCND2</i> and <i>CCND3</i>, encoding cyclin D2 and D3, respectively, have been identified in MCL lacking the t(11;14)(q13;q32) translocation<sup><a href="#ref-1">1</a></sup>. However, over the past decade, further investigation into the pathogenesis of MCL has defined other molecular abnormalities that define cyclin D1-negative MCL.</p><p class="" id=d35442e208>SOX11, a SOX family transcription factor with a role in cell fate and differentiation, has been identified as a reliable diagnostic and prognostic marker of MCL in both cyclin D1-positive and -negative disease<sup><a href="#ref-2">2</a></sup>. Microarray analyses and protein expression quantification by immunohistochemistry (IHC) have shown that SOX11 overexpression is an independent molecular feature of MCL regardless of cyclin D1 status. Furthermore, a complex transcription signature accompanies the overexpression of SOX11. This includes the regulation of the transcription factor PAX5, which is critical for late B-cell differentiation<sup><a href="#ref-3">3</a></sup>. Increased PAX5 levels repress the key transcriptional regulators of plasma cell differentiation BLIMP1, XB1, and IRF4. Supporting this, increased SOX11 expression correlates with an unmutated or minimally mutated <i>IGHV</i> genotype, a marker of germinal center maturation and differentiation into memory B-cells<sup><a href="#ref-4">4</a></sup>. Loss of SOX11 expression, and subsequent downregulation of PAX5, correlates with a hypermutated <i>IGHV</i> genotype, reflective of early steps towards plasma cell differentiation. Clinically, low SOX11 expression correlates with a more indolent and non-nodal leukemic phase presentation, whereas increased SOX11 expression portends a more aggressive phenotype with nodal and extra-nodal sites of involvement. Taken together, the implementation of <i>CCND2, CCND3,</i> SOX11, and <i>IGHV</i> analysis has expanded criteria for the molecular diagnosis of MCL.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d35442e239>Prognostic variables and observation in mantle cell lymphoma</h2><p class="" id=d35442e242>MCL is thought to be an aggressive disease in most patients, associated with early relapse and poor long-term survival. Standard of care strategies continue to emphasize aggressive treatment approaches, which have demonstrated the longest durable remissions. However, observation can be considered in patients with favorable disease features<sup><a href="#ref-5">5</a>,<a href="#ref-6">6</a></sup>. Easily obtained clinical variables provide excellent risk stratification of patients. The MCL International Prognostic Index (MIPI) incorporates patient age, performance status, lactate dehydrogenase (LDH), and white blood cell count into a formula to stratify patients as low, intermediate, or high risk; 5-year overall survival for MIPI-low patients was 83% compared with 34% in MIPI-high patients, with a high MIPI score also predicting inferior response to therapy<sup><a href="#ref-7">7</a></sup>. A similar tool, the Biologic MIPI, incorporates the Ki-67 proliferation rate, usually readily obtained from pathology specimens, to better identify high-risk disease<sup><a href="#ref-8">8</a></sup>.</p><p class="" id=d35442e260>Among the various clinical and pathologic factors analyzed in a population-based study reported by the British Columbia Cancer Agency (n=440), non-nodal presentation, defined as patients presenting with lymphocytosis and/or splenomegaly, was the single factor most strongly associated with prolonged time to treatment and excellent overall survival. In this study, median time to treatment was 35 months without a negative impact on overall survival in patients deemed suitable for initial observation. Other characteristics of the observed patients included good performance status, absence of B-symptoms, non-blastoid morphology, and Ki67 percentage of less than 30%. There were no significant differences in the observed versus treatment groups, including in age at diagnosis, sex, leukocyte count, platelet count, stage, TP53 and SOX11 expression by IHC, and MIPI risk score<sup><a href="#ref-5">5</a></sup>.</p><p class="" id=d35442e267>While there are no prospective data guiding observation in patients based on SOX11 or TP53 expression, these are additional variables that can be considered clinically to predict disease course. In the British Columbia study above, P53 positivity was defined as strong nuclear staining and SOX11 was positive if any cells stained positive. A second study by the European MCL Network sorted patients into groups based on percentage of P53-positive cells (1–10%, 10–50%, and over 50%) and SOX11 cells (0%, 1–10%, and over 10%) by IHC<sup><a href="#ref-9">9</a></sup>. In this study, the cohort with over 50% TP53 expression had poorer prognosis, while SOX11 expression was not a reliable prognostic marker, possibly owing to an under-representation of patients with non-nodal disease. Another explanation is a difference in methods to determine SOX11 positivity, as Navarro <i>et al</i>. used a combination of reverse transcriptase polymerase chain reaction (RT-PCR) to measure SOX11 RNA, IHC to measure SOX11 protein, and gene expression profiling and observed an improved clinical outcome with low SOX11 expression.</p><p class="" id=d35442e277>It is important to note that no patients in the above cohorts were observed with the pathologic blastoid variant of MCL, which continues to be a clinical challenge<sup><a href="#ref-10">10</a></sup>. This group, which comprises less than 20% of total MCL diagnoses, features medium-sized lymphocytes with indistinct cytoplasm and dispersed chromatin compared with classical-type MCL with smaller lymphocytes and condensed chromatin. In a subgroup analysis of all modern trials, the patients with blastoid phenotype have inferior survival and remission rates. A further understanding of the disease process in these patients is greatly needed for the development of novel therapies. Thus, when deciding on initial observations, we consider all of the aforementioned disease features and balance this with the patient’s preferences and other comorbidities. It should be remembered that many patients will not behave as their risk features predict, so close monitoring for progression of disease is necessary in all observed patients.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d35442e287>Treatment strategies in fit patients</h2><div class=section><a name=d35442e290 class=n-a></a><h3 class=section-title>Induction chemotherapy</h3><p class="" id=d35442e295>Once the decision is made to proceed with treatment, the oncologist must determine whether or not the patient is fit for intensive therapy. Treatment broadly consists of two components: cytarabine-containing induction chemotherapy followed by ASCT. Phase II trials in the past decade have consistently demonstrated the impressive activity of cytarabine in MCL, namely in the Hyper-CVAD and VcR-CVAD regimens<sup><a href="#ref-11">11</a>–<a href="#ref-13">13</a></sup>. Since that time, the MCL Younger trial conducted by the European MCL Network provided phase III data to support cytarabine as the key agent in MCL induction<sup><a href="#ref-14">14</a></sup>. This trial included patients aged 65 years or younger with stage II–IV MCL randomized to six cycles of R-CHOP (non-cytarabine group) versus alternating R-CHOP and R-DHAP for six cycles (cytarabine group). Patients then proceeded to ASCT with myeloablative conditioning. Time to treatment failure in the cytarabine group was 9.1 years compared with 3.9 years in the non-cytarabine cohort, a benefit attributed to deeper molecular responses in patients receiving cytarabine. This benefit came at the expense of higher hematologic and gastrointestinal toxicities. The impressive results of the MCL Younger trial have redefined the standard treatment paradigm for fit patients with MCL but also raise a number of interesting questions going forward. Ongoing long-term follow-up of the trial will demonstrate whether cytarabine immunochemotherapy results in treatment cures in certain patients, although long-term follow-up of the Nordic trial suggests that this may still not be the case<sup><a href="#ref-15">15</a>,<a href="#ref-16">16</a></sup>. Additionally, it is unclear how much benefit cytarabine immunochemotherapy provides for blastoid-variant MCL, a cohort that made up less than 10% of the population in the MCL Younger trial. Similarly, among the 5% of patients with a high combined MIPI and Ki-67 expression score treated in the European MCL Network Younger trial, median overall survival was approximately 2 years<sup><a href="#ref-8">8</a></sup>. Each of these patient subsets still perform poorly, even with modern cytarabine-containing regimens and/or ASCT, suggesting that novel treatment strategies are needed for these groups.</p><p class="" id=d35442e320>The use of ASCT consolidation in first remission is supported by data published by the European and Nordic groups who noted significantly prolonged progression-free survival (PFS) with ASCT<sup><a href="#ref-15">15</a></sup>, with the European group randomizing patients to interferon versus ASCT<sup><a href="#ref-17">17</a></sup>. However, these data were attained before the widespread use of cytarabine induction regimens, maintenance rituximab in first remission, and the discovery of BTK inhibitors. Thus, randomized data confirming the efficacy of ASCT are greatly needed given the number of novel strategies recently developed in MCL. The European MCL Network phase III TRIANGLE study is currently randomizing patients to an induction regimen containing the BTK inhibitor ibrutinib while also assessing whether an ibrutinib-containing induction regimen with maintenance can replace ASCT. This will be the first phase III trial to incorporate a targeted molecular therapy into the MCL induction regimen and also the first randomized study to test the efficacy of ASCT in the cytarabine and rituximab era.</p></div><div class=section><a name=d35442e332 class=n-a></a><h3 class=section-title>Post-transplant maintenance and surveillance</h3><p class="" id=d35442e337>While most patients have no evidence of disease post-ASCT, the high relapse rate of MCL supports the concept of undetectable minimal residual disease (MRD) that precedes the development of a clinical relapse. This has been most rigorously studied by the Nordic MCL Group, who have measured MRD both pre- and post-ASCT by designing individualized RT-PCR primers to detect clonal <i>IgH</i> rearrangements on bone marrow and peripheral blood samples<sup><a href="#ref-18">18</a></sup>. Seroconversion to positive RT-PCR or a fivefold increase in RT-PCR MRD levels was defined as a molecular relapse (but not counted as a clinical relapse). Followed prospectively, PFS in MRD-negative patients was 142 months compared with 35 months in MRD-positive patients. This improvement in PFS also correlated with an impressive overall survival advantage. While certainly a proof of concept, there is currently no wide-scale approach for measuring MRD in large numbers of patients, and these methods will require validation across more institutions. The absence of such a universal approach has prompted the investigation of maintenance rituximab to produce more durable long-term remissions post-ASCT<sup><a href="#ref-19">19</a></sup>. The Nordic group first showed that pre-emptive treatment with four doses of rituximab at first sign of molecular relapse led to a re-induction of molecular remission in over 90% of patients<sup><a href="#ref-20">20</a></sup>. Prospective phase III data to support maintenance rituximab have become available with the recent published results of the multicenter LyMa trial conducted in France<sup><a href="#ref-21">21</a></sup>. Patients were randomized in a 1:1 ratio, irrespective of MRD status, to observation versus 3 years of maintenance rituximab after four cycles of R-DHAP induction followed by ASCT. PFS at 4 years was 79% in the rituximab group versus 61% with observation alone. Importantly, rituximab maintenance provided a statistically significant overall survival advantage and thus should be considered a standard of care post-ASCT. What remains unanswered, however, is whether consolidative ASCT provides any additional benefit in the rituximab maintenance era. A major advance towards this question is currently underway in a phase III ECOG trial that is randomizing patients without MRD to autologous transplant with maintenance rituximab to rituximab alone (<a href="#T1">Table 1</a>). Additionally, investigation into the feasibility and efficacy of ibrutinib as an alternative for (or adjuct to) rituximab and as a replacement for ASCT will be addressed in the phase III TRIANGLE study and a phase II trial currently enrolling at our institution (<a href="#T1">Table 1</a>).</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Current clinical trials in mantle cell lymphoma (MCL).</h3><p id=d35442e376>Notable current clinical trials in MCL organized by clinical indication. Certain trials appear twice given their design to answer multiple clinical questions. ASCT, autologous stem cell transplant; BCL-2, B-cell lymphoma 2; BR, bendamustine–rituximab; BTK, Bruton’s tyrosine kinase; CAR-T; chimeric antigen receptor T-cell; HDAC, histone deacetylase; R-Hyper-CVAD, rituximab plus fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone plus methotrexate and cytarabine; MRD, minimal residual disease; PI3K, phosphoinositide 3-kinase; R<sup>2</sup>, lenalidomide plus rituximab; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone; R-DHAP, rituximab, dexamethasone, cytarabine, and cisplatin; R-HAD, rituximab, high-dose cytarabine, and dexamethasone.</p></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d35442e383 class=n-a></a><thead><a name=d35442e385 class=n-a></a><tr><a name=d35442e387 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d35442e389 class=n-a></a>Category of<br class=br>therapy</th><th align=left colspan=1 rowspan=1 valign=top><a name=d35442e394 class=n-a></a>Study design or regimen</th><th align=left colspan=1 rowspan=1 valign=top><a name=d35442e397 class=n-a></a>Target or drug class</th><th align=left colspan=1 rowspan=1 valign=top><a name=d35442e400 class=n-a></a>Clinical trials<br class=br>identifier</th><th align=left colspan=1 rowspan=1 valign=top><a name=d35442e405 class=n-a></a>Status</th><th align=left colspan=1 rowspan=1 valign=top><a name=d35442e409 class=n-a></a>Phase</th></tr></thead><tbody><a name=d35442e414 class=n-a></a><tr><a name=d35442e416 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d35442e418 class=n-a></a> <b> <span style="text-decoration: underline">Fit induction</span> </b> </td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e427 class=n-a></a>R-CHOP/R-DHAP + ASCT vs.<br class=br>R-CHOP/R-DHAP + ibrutinib vs.<br class=br>R-CHOP/R-DHAP + ibrutinib + ASCT</td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e434 class=n-a></a>BTK</td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e437 class=n-a></a>NCT02858258<br class=br>(TRIANGLE)</td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e442 class=n-a></a>Recruiting</td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e446 class=n-a></a>Phase III</td></tr><tr><a name=d35442e450 class=n-a></a><td colspan=1 rowspan=1><a name=d35442e451 class=n-a></a></td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e453 class=n-a></a>R-HyperCVAD + Ibrutinib</td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e456 class=n-a></a>BTK</td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e459 class=n-a></a>NCT02427620</td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e462 class=n-a></a>Recruiting</td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e465 class=n-a></a>Phase II</td></tr><tr><a name=d35442e469 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d35442e471 class=n-a></a> <b> <span style="text-decoration: underline">Unfit induction</span> </b> </td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e480 class=n-a></a>BR + ibrutinib</td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e483 class=n-a></a>BTK</td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e486 class=n-a></a>NCT01776840<br class=br>(SHINE)</td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e491 class=n-a></a>Active</td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e495 class=n-a></a>Phase III</td></tr><tr><a name=d35442e499 class=n-a></a><td colspan=1 rowspan=1><a name=d35442e500 class=n-a></a></td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e502 class=n-a></a>R-CHOP/R-HAD vs. R-CHOP</td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e505 class=n-a></a>Cytarabine</td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e508 class=n-a></a>NCT01865110</td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e511 class=n-a></a>Recruiting</td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e514 class=n-a></a>Phase III</td></tr><tr><a name=d35442e518 class=n-a></a><td colspan=1 rowspan=1><a name=d35442e519 class=n-a></a></td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e521 class=n-a></a>BR + acalabrutinib</td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e524 class=n-a></a>BTK</td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e527 class=n-a></a>NCT02972840</td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e530 class=n-a></a>Recruiting</td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e533 class=n-a></a>Phase III</td></tr><tr><a name=d35442e538 class=n-a></a><td colspan=1 rowspan=1><a name=d35442e539 class=n-a></a></td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e541 class=n-a></a>Bendamustine + obinutuzumab</td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e544 class=n-a></a>Anti-CD20</td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e547 class=n-a></a>NCT03311126</td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e550 class=n-a></a>Recruiting</td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e553 class=n-a></a>Phase II</td></tr><tr><a name=d35442e557 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d35442e559 class=n-a></a> <b> <span style="text-decoration: underline">Maintenance</span> </b> </td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e568 class=n-a></a>Rituximab vs. ASCT + rituximab in<br class=br>MRD-negative patients</td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e573 class=n-a></a>Anti-CD20</td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e576 class=n-a></a>NCT03267433</td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e579 class=n-a></a>Recruiting</td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e583 class=n-a></a>Phase III</td></tr><tr><a name=d35442e587 class=n-a></a><td colspan=1 rowspan=1><a name=d35442e588 class=n-a></a></td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e590 class=n-a></a>ASCT +/- ibrutinib maintenance vs<br class=br>ibrutinib maintenance (no ASCT);<br class=br>rituximab may be added to each arm</td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e597 class=n-a></a>BTK</td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e600 class=n-a></a>NCT02858258<br class=br>(TRIANGLE)</td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e605 class=n-a></a>Recruiting</td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e608 class=n-a></a>Phase III</td></tr><tr><a name=d35442e612 class=n-a></a><td colspan=1 rowspan=1><a name=d35442e613 class=n-a></a></td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e615 class=n-a></a>Ibrutinib without ASCT</td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e618 class=n-a></a>BTK</td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e621 class=n-a></a>NCT02242097</td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e624 class=n-a></a>Recruiting</td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e627 class=n-a></a>Phase II</td></tr><tr><a name=d35442e631 class=n-a></a><td colspan=1 rowspan=1><a name=d35442e632 class=n-a></a></td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e634 class=n-a></a>R<sup>2</sup> vs. rituximab maintenance</td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e640 class=n-a></a>Anti-CD20 + Imid</td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e643 class=n-a></a>NCT01865110</td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e646 class=n-a></a>Recruiting</td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e649 class=n-a></a>Phase III</td></tr><tr><a name=d35442e653 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d35442e655 class=n-a></a> <b> <span style="text-decoration: underline">Relapsed MCL</span> </b> </td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e664 class=n-a></a>Obinutuzumab + GDC-0199 +<br class=br>Ibrutinib</td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e669 class=n-a></a>Anti-CD20, BCL-2, BTK</td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e672 class=n-a></a>NCT02558816</td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e675 class=n-a></a>Recruiting</td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e679 class=n-a></a>Phase II</td></tr><tr><a name=d35442e684 class=n-a></a><td colspan=1 rowspan=1><a name=d35442e685 class=n-a></a></td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e687 class=n-a></a>Obinutuzumab + Ibrutinib</td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e690 class=n-a></a>Anti-CD20 + BTK</td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e693 class=n-a></a>NCT02736617</td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e696 class=n-a></a>Recruiting</td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e699 class=n-a></a>Phase II</td></tr><tr><a name=d35442e703 class=n-a></a><td colspan=1 rowspan=1><a name=d35442e704 class=n-a></a></td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e706 class=n-a></a>KTE-C19</td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e709 class=n-a></a>CAR-T</td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e712 class=n-a></a>NCT02601313<br class=br>(ZUMA-2)</td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e717 class=n-a></a>Recruiting</td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e720 class=n-a></a>Phase II</td></tr><tr><a name=d35442e724 class=n-a></a><td colspan=1 rowspan=1><a name=d35442e725 class=n-a></a></td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e727 class=n-a></a>JCAR017</td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e730 class=n-a></a>CAR-T</td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e733 class=n-a></a>NCT02631044<br class=br>(TRANSCEND)</td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e738 class=n-a></a>Recruiting</td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e741 class=n-a></a>Phase I</td></tr><tr><a name=d35442e745 class=n-a></a><td colspan=1 rowspan=1><a name=d35442e746 class=n-a></a></td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e748 class=n-a></a>Ixazomib + Ibrutinib</td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e751 class=n-a></a>Proteasome + BTK</td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e754 class=n-a></a>NCT03323151</td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e757 class=n-a></a>Recruiting</td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e760 class=n-a></a>Phase II</td></tr><tr><a name=d35442e764 class=n-a></a><td colspan=1 rowspan=1><a name=d35442e765 class=n-a></a></td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e767 class=n-a></a>Bortezomib + Ibrutinib</td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e770 class=n-a></a>Proteasome + BTK</td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e773 class=n-a></a>NCT02356458</td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e776 class=n-a></a>Recruiting</td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e779 class=n-a></a>Phase II</td></tr><tr><a name=d35442e783 class=n-a></a><td colspan=1 rowspan=1><a name=d35442e784 class=n-a></a></td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e786 class=n-a></a>INCB050465</td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e789 class=n-a></a>PI3K</td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e792 class=n-a></a>NCT03235544</td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e795 class=n-a></a>Recruiting</td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e798 class=n-a></a>Phase II</td></tr><tr><a name=d35442e803 class=n-a></a><td colspan=1 rowspan=1><a name=d35442e804 class=n-a></a></td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e806 class=n-a></a>Entospletinib</td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e809 class=n-a></a>Syc</td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e812 class=n-a></a>NCT01799889</td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e815 class=n-a></a>Active</td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e818 class=n-a></a>Phase II</td></tr><tr><a name=d35442e822 class=n-a></a><td colspan=1 rowspan=1><a name=d35442e823 class=n-a></a></td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e825 class=n-a></a>Vorinostat</td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e828 class=n-a></a>HDAC</td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e831 class=n-a></a>NCT00875056</td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e834 class=n-a></a>Recruiting</td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e837 class=n-a></a>Phase II</td></tr><tr><a name=d35442e841 class=n-a></a><td colspan=1 rowspan=1><a name=d35442e842 class=n-a></a></td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e844 class=n-a></a>Enzalutamide</td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e847 class=n-a></a>Androgen</td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e850 class=n-a></a>NCT02489123</td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e853 class=n-a></a>Recruiting</td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e856 class=n-a></a>Phase II</td></tr></tbody></table></div><p class="" id=d35442e863>It is important to analyze the results of the LyMa trial in the context of the MCL Younger trial. The LyMa trial produced impressive results with an anthracycline and alkylating-free induction regimen. Patients who failed to respond to four cycles of R-DHAP proceeded to salvage R-CHOP prior to transplant. This stepwise progression spared over 90% of the study participants from additional cytotoxic chemotherapy exposure and their associated long-term toxicities.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d35442e870>Therapy strategies in unfit patients</h2><p class="" id=d35442e873>The treatment paradigm in MCL changes when patient preferences or comorbidities preclude intensive therapies including ASCT. In this scenario, clinical judgment should drive the safest and most-effective induction chemotherapy regimen. A phase III randomized trial established superiority of R-CHOP over fludarabine plus cyclophosphamide in unfit patients with a median age of 70 and confirmed the benefit of lifetime rituximab maintenance in responders<sup><a href="#ref-22">22</a></sup>. Since this study, a number of regimens have shown marked improvement in clinical outcomes over R-CHOP (<a href="#T2">Table 2</a>). MCL patients comprised approximately 15–20% of the total treated population in two recent phase III studies demonstrating non-inferiority of bendamustine–rituximab (BR) to R-CHOP<sup><a href="#ref-23">23</a>,<a href="#ref-24">24</a></sup>. BR demonstrated an improved safety profile and PFS that carried through into the MCL subgroup analysis. It should be noted that while these trials were designed for elderly patients with non-aggressive NHL, the median age difference compared with the MCL Younger study was a modest 5–10 years. Therefore, as is probably true in oncology in general, the decision of intensive treatment should be based more on performance status and goals of therapy than absolute age alone.</p><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Regimens for mantle cell lymphoma (MCL).</h3><p id=d35442e900>This table presents treatment regimens for MCL organized by clinical indication. BR, bendamustine–rituximab; CRR, complete response rate; CrU, unconfirmed complete response rate; LBR, lenalidomide, bendamustine, and rituximab; ORR, overall response rate; NR, not reported; R<sup>2</sup>, lenalidomide plus rituximab; R-BAC(500), rituximab, bendamustine, and cytarabine with low-dose cytarabine; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone; R-DHAP, rituximab, dexamethasone, cytarabine, and cisplatin; R-Hyper-CVAD, rituximab plus fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone; RiBVD, rituximab, bendamustine, bortezomib, and dexamethasone; VcR-CVAD, bortezomib, rituximab, hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone; VR-CAP, bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone.</p></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d35442e907 class=n-a></a><thead><a name=d35442e909 class=n-a></a><tr><a name=d35442e911 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d35442e913 class=n-a></a>Treatment category</th><th align=left colspan=1 rowspan=1 valign=top><a name=d35442e916 class=n-a></a>Regimen</th><th align=left colspan=1 rowspan=1 valign=top><a name=d35442e919 class=n-a></a>Number of<br class=br>patients</th><th align=left colspan=1 rowspan=1 valign=top><a name=d35442e924 class=n-a></a>ORR</th><th align=left colspan=1 rowspan=1 valign=top><a name=d35442e927 class=n-a></a>CRR (CrU)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d35442e931 class=n-a></a>Reference</th></tr></thead><tbody><a name=d35442e936 class=n-a></a><tr><a name=d35442e938 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d35442e940 class=n-a></a><b><span style="text-decoration: underline">Fit patients</span></b></td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e945 class=n-a></a>R-Hyper-CVAD</td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e948 class=n-a></a>97</td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e951 class=n-a></a>97%</td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e954 class=n-a></a>77% (87%)</td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e958 class=n-a></a><a href="#ref-12">12</a></td></tr><tr><a name=d35442e963 class=n-a></a><td colspan=1 rowspan=1><a name=d35442e964 class=n-a></a></td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e966 class=n-a></a>VcR-CVAD</td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e969 class=n-a></a>75</td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e972 class=n-a></a>95%</td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e975 class=n-a></a>68%</td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e978 class=n-a></a><a href="#ref-11">11</a></td></tr><tr><a name=d35442e983 class=n-a></a><td colspan=1 rowspan=1><a name=d35442e984 class=n-a></a></td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e986 class=n-a></a>R-DHAP x 4</td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e989 class=n-a></a>299</td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e992 class=n-a></a>89%</td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e995 class=n-a></a>41% (77%)</td><td align=left colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d35442e998 class=n-a></a><a href="#ref-20">20</a></td></tr><tr><a name=d35442e1003 class=n-a></a><td colspan=1 rowspan=1><a name=d35442e1004 class=n-a></a></td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e1006 class=n-a></a>R-DHAP/R-CHOP x 6</td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e1009 class=n-a></a>248</td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e1012 class=n-a></a>94%</td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e1015 class=n-a></a>55% (91%)</td><td align=left colspan=1 rowspan=1 style="background-color:#DEEAF6;" valign=top><a name=d35442e1018 class=n-a></a><a href="#ref-13">13</a></td></tr><tr><a name=d35442e1023 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d35442e1025 class=n-a></a> <b> <span style="text-decoration: underline">Unfit patients</span> </b> </td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e1034 class=n-a></a>BR</td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e1037 class=n-a></a>50</td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e1040 class=n-a></a>94%</td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e1043 class=n-a></a>50%</td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e1047 class=n-a></a><a href="#ref-22">22</a></td></tr><tr><a name=d35442e1053 class=n-a></a><td colspan=1 rowspan=1><a name=d35442e1054 class=n-a></a></td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e1056 class=n-a></a>RiBVD</td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e1059 class=n-a></a>74</td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e1062 class=n-a></a>86%</td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e1065 class=n-a></a>NR (74%)</td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e1068 class=n-a></a><a href="#ref-24">24</a></td></tr><tr><a name=d35442e1073 class=n-a></a><td colspan=1 rowspan=1><a name=d35442e1074 class=n-a></a></td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e1076 class=n-a></a>LBR</td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e1079 class=n-a></a>50</td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e1082 class=n-a></a>88%</td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e1085 class=n-a></a>32% (64%)</td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e1088 class=n-a></a><a href="#ref-25">25</a></td></tr><tr><a name=d35442e1093 class=n-a></a><td colspan=1 rowspan=1><a name=d35442e1094 class=n-a></a></td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e1096 class=n-a></a>R<sup>2</sup></td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e1101 class=n-a></a>38</td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e1104 class=n-a></a>92%</td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e1107 class=n-a></a>64%</td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e1110 class=n-a></a><a href="#ref-26">26</a></td></tr><tr><a name=d35442e1115 class=n-a></a><td colspan=1 rowspan=1><a name=d35442e1116 class=n-a></a></td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e1118 class=n-a></a>VR-CAP</td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e1121 class=n-a></a>229</td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e1124 class=n-a></a>92%</td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e1127 class=n-a></a>53%</td><td align=left colspan=1 rowspan=1 style="background-color:#C5E0B3;" valign=top><a name=d35442e1130 class=n-a></a><a href="#ref-27">27</a></td></tr><tr><a name=d35442e1135 class=n-a></a><td colspan=1 rowspan=1><a name=d35442e1136 class=n-a></a></td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e1138 class=n-a></a>R-BAC(500)</td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e1141 class=n-a></a>57</td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e1144 class=n-a></a>NR</td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e1147 class=n-a></a>91%</td><td align=left colspan=1 rowspan=1 style="background-color:#E2EFD9" valign=top><a name=d35442e1150 class=n-a></a><a href="#ref-28">28</a></td></tr><tr><a name=d35442e1155 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d35442e1157 class=n-a></a><b><span style="text-decoration: underline">Relapsed disease</span></b></td><td align=left colspan=1 rowspan=1 style="background-color:#FFE599;" valign=top><a name=d35442e1162 class=n-a></a>Bortezomib</td><td align=left colspan=1 rowspan=1 style="background-color:#FFE599;" valign=top><a name=d35442e1165 class=n-a></a>155</td><td align=left colspan=1 rowspan=1 style="background-color:#FFE599;" valign=top><a name=d35442e1168 class=n-a></a>33%</td><td align=left colspan=1 rowspan=1 style="background-color:#FFE599;" valign=top><a name=d35442e1171 class=n-a></a>6% (8%)</td><td align=left colspan=1 rowspan=1 style="background-color:#FFE599;" valign=top><a name=d35442e1175 class=n-a></a><a href="#ref-29">29</a></td></tr><tr><a name=d35442e1181 class=n-a></a><td colspan=1 rowspan=1><a name=d35442e1182 class=n-a></a></td><td align=left colspan=1 rowspan=1 style="background-color:#FFF2CC;" valign=top><a name=d35442e1184 class=n-a></a>Temsirolimus</td><td align=left colspan=1 rowspan=1 style="background-color:#FFF2CC;" valign=top><a name=d35442e1187 class=n-a></a>54</td><td align=left colspan=1 rowspan=1 style="background-color:#FFF2CC;" valign=top><a name=d35442e1190 class=n-a></a>22%</td><td align=left colspan=1 rowspan=1 style="background-color:#FFF2CC;" valign=top><a name=d35442e1193 class=n-a></a>2%</td><td align=left colspan=1 rowspan=1 style="background-color:#FFF2CC;" valign=top><a name=d35442e1196 class=n-a></a><a href="#ref-30">30</a></td></tr><tr><a name=d35442e1201 class=n-a></a><td colspan=1 rowspan=1><a name=d35442e1202 class=n-a></a></td><td align=left colspan=1 rowspan=1 style="background-color:#FFE599;" valign=top><a name=d35442e1204 class=n-a></a>Lenolidamide</td><td align=left colspan=1 rowspan=1 style="background-color:#FFE599;" valign=top><a name=d35442e1207 class=n-a></a>170</td><td align=left colspan=1 rowspan=1 style="background-color:#FFE599;" valign=top><a name=d35442e1210 class=n-a></a>78%</td><td align=left colspan=1 rowspan=1 style="background-color:#FFE599;" valign=top><a name=d35442e1213 class=n-a></a>19% (11%)</td><td align=left colspan=1 rowspan=1 style="background-color:#FFE599;" valign=top><a name=d35442e1216 class=n-a></a><a href="#ref-31">31</a></td></tr><tr><a name=d35442e1221 class=n-a></a><td colspan=1 rowspan=1><a name=d35442e1222 class=n-a></a></td><td align=left colspan=1 rowspan=1 style="background-color:#FFF2CC;" valign=top><a name=d35442e1224 class=n-a></a>Ibrutinib</td><td align=left colspan=1 rowspan=1 style="background-color:#FFF2CC;" valign=top><a name=d35442e1227 class=n-a></a>139</td><td align=left colspan=1 rowspan=1 style="background-color:#FFF2CC;" valign=top><a name=d35442e1230 class=n-a></a>72%</td><td align=left colspan=1 rowspan=1 style="background-color:#FFF2CC;" valign=top><a name=d35442e1233 class=n-a></a>19%</td><td align=left colspan=1 rowspan=1 style="background-color:#FFF2CC;" valign=top><a name=d35442e1236 class=n-a></a><a href="#ref-8">8</a></td></tr><tr><a name=d35442e1241 class=n-a></a><td colspan=1 rowspan=1><a name=d35442e1242 class=n-a></a></td><td align=left colspan=1 rowspan=1 style="background-color:#FFE599;" valign=top><a name=d35442e1244 class=n-a></a>Acalabrutinib</td><td align=left colspan=1 rowspan=1 style="background-color:#FFE599;" valign=top><a name=d35442e1247 class=n-a></a>124</td><td align=left colspan=1 rowspan=1 style="background-color:#FFE599;" valign=top><a name=d35442e1250 class=n-a></a>81%</td><td align=left colspan=1 rowspan=1 style="background-color:#FFE599;" valign=top><a name=d35442e1253 class=n-a></a>40%</td><td align=left colspan=1 rowspan=1 style="background-color:#FFE599;" valign=top><a name=d35442e1256 class=n-a></a><a href="#ref-32">32</a></td></tr><tr><a name=d35442e1261 class=n-a></a><td colspan=1 rowspan=1><a name=d35442e1262 class=n-a></a></td><td align=left colspan=1 rowspan=1 style="background-color:#FFF2CC;" valign=top><a name=d35442e1264 class=n-a></a>Ibrutinib + Venetoclax</td><td align=left colspan=1 rowspan=1 style="background-color:#FFF2CC;" valign=top><a name=d35442e1267 class=n-a></a>24</td><td align=left colspan=1 rowspan=1 style="background-color:#FFF2CC;" valign=top><a name=d35442e1270 class=n-a></a>71%</td><td align=left colspan=1 rowspan=1 style="background-color:#FFF2CC;" valign=top><a name=d35442e1273 class=n-a></a>62%</td><td align=left colspan=1 rowspan=1 style="background-color:#FFF2CC;" valign=top><a name=d35442e1276 class=n-a></a><a href="#ref-33">33</a></td></tr></tbody></table></div><p class="" id=d35442e1284>A number of studies have attempted to improve the efficacy of the BR backbone in elderly patients by including agents which have shown efficacy in relapsed disease. These include phase II data demonstrating the efficacy of adding bortezomib, dexamethasone, and lenalidomide (RiBVD)<sup><a href="#ref-25">25</a></sup>, lenalidomide (LBR)<sup><a href="#ref-28">28</a></sup>, or cytarabine (R-BAC500)<sup><a href="#ref-26">26</a></sup>. The results of the phase III SHINE study combining BR with ibrutinib should be available in the upcoming year. It is also possible to spare certain patients alkylating chemotherapy, as an 85% PFS was achieved with a 12-cycle regimen of lenalidomide plus rituximab (R<sup>2</sup>)<sup><a href="#ref-27">27</a></sup>. Improved PFS was observed in the phase III LYM-3002 study by substituting bortezomib for vincristine in the VR-CAP regimen in a patient population with a median age of 65<sup><a href="#ref-29">29</a></sup>. Given these results, our preference has been to utilize these newer regimens with rituximab maintenance over traditional R-CHOP alone in unfit patients, with options summarized in <a href="#T2">Table 2</a>, tailored to patients based on tolerability, comorbid conditions, and performance status.</p><p class="" id=d35442e1314>As mentioned above, based on the success of cytarabine-containing induction regimens in younger fit patients, the Italian MCL group studied its addition to a BR backbone in elderly patients (R-BAC500)<sup><a href="#ref-26">26</a></sup>. Rather than three doses at 2 g/m<sup>2</sup> in the MCL younger trial (D-HAP regimen), the investigators lowered the cytarabine dose to three doses at 500 mg/m<sup>2</sup> per cycle. This produced an acceptable hematological toxicity profile that allowed 95% of patients to complete four cycles of therapy. PFS was approximately 75% at 3 years in a patient population with a median age of 71, an impressive result given rituximab maintenance was not included in the protocol. These results warrant confirmation in a randomized setting and may prove to be the next major advance to sustainable remissions in the elderly population.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d35442e1331>Relapsed mantle cell lymphoma</h2><p class="" id=d35442e1334>Relapsed MCL has historically been characterized by poor response rates and an overall survival of less than 3 years. However, the past decade has seen multiple agents approved with single agent efficacy in relapsed disease. First, the proteasome inhibitor bortezomib received FDA approval in MCL based upon phase II clinical data demonstrating a median PFS of approximately 6 months<sup><a href="#ref-30">30</a></sup>. A multicenter open-label phase III study demonstrated superiority of temsirolimus to investigator’s choice therapy with a median PFS of 4.8 months, leading to its approval in Europe<sup><a href="#ref-34">34</a></sup>. Third, the phase II EMERGE trial confirmed the activity of lenalidomide in patients with progression of disease on bortezomib, with an overall response rate (ORR) of 28% in a heavily pre-treated population and durable efficacy with long-term follow-up, leading to lenalidomide’s approval in the US<sup><a href="#ref-31">31</a>,<a href="#ref-35">35</a></sup>. Subsequently, the SPRINT trial conducted by the European MCL Network randomized 254 patients to receive lenalidomide versus investigator’s choice treatment and found a median PFS of 8.7 months in the lenalidomide group compared with 5.2 months in the control population<sup><a href="#ref-36">36</a></sup>. In an international phase II trial in relapsed MCL patients treated with single-agent ibrutinib and included patients previously exposed to bortezomib<sup><a href="#ref-32">32</a></sup>, a 17.5-month PFS survival was observed. Lastly, pre-existing atrial fibrillation and need for anticoagulation has limited the use of ibrutinib in certain patients and led to the development and approval of the selective BTK inhibitor acalabrutinib. Phase II data have shown a favorable safety profile and durable remissions with this agent, but its non-inferiority or superiority to ibrutinib has not been tested<sup><a href="#ref-37">37</a></sup>. Nonetheless, this agent has also recently received FDA approval for relapsed/refractory MCL.</p><p class="" id=d35442e1365>The impressive PFS of single-agent ibrutinib prompted a European phase III multicenter study comparing single-agent ibrutinib with temsirolimus<sup><a href="#ref-33">33</a></sup>. Median PFS in patients with ibrutinib was 14.2 months compared with 6.2 months in the temsirolimus cohort, confirming prior phase II data. Importantly, ibrutinib was associated with fewer treatment-related adverse effects. While the difference in overall survival was not significant between the two groups, 23% of patients assigned to temsirolimus subsequently received ibrutinib at relapse, perhaps confounding the overall survival data. This study is the highest-quality evidence supporting ibrutinib as standard of care in patients with relapsed MCL.</p><p class="" id=d35442e1372>Multiple efforts are now underway to combine the small molecule inhibitors with single agent activity in relapsed and refractory MCL (<a href="#T1">Table 1</a>). Most recently, promising phase II data combining ibrutinib and the BCL-2 inhibitor venetoclax in 24 patients achieved a 42% complete response rate (CRR) compared with a 9% CRR in historical controls<sup><a href="#ref-38">38</a>,<a href="#ref-39">39</a></sup>. The efficacy and safety of this combination will have to be confirmed in a larger cohort, but this is an early indication that synergism between single agents may be a fruitful strategy in this disease.</p><p class="" id=d35442e1385>For patients who unfortunately fail to respond to the traditional and novel therapies, allogeneic stem cell transplant (allo-SCT) remains a salvage option for disease control<sup><a href="#ref-40">40</a>,<a href="#ref-41">41</a></sup>. It is difficult to know the exact benefit of allo-SCT given the lack of randomized data in a population with few alternative options. However, the German group produced 5-year PFS rates of 67% in this high-risk group with plateauing survival curves that suggest some of these patients may be cured. This benefit, not surprisingly, comes at the cost of a treatment-related mortality rate of approximately 25%. As in all cases of allo-SCT, a referral to a high-volume transplant center is key for the best outcome.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d35442e1398>New insights into mantle cell lymphoma pathogenesis and future therapies</h2><p class="" id=d35442e1401>Despite the promising single agent efficacy of ibrutinib, more options are badly needed for patients with relapsed disease given the 1-year overall survival rate of approximately 70% in the ibrutinib era<sup><a href="#ref-33">33</a></sup>. Recent studies into mechanisms for ibrutinib resistance have identified the upregulation of NF-κB signaling as an adaptive mechanism to bypass the antigen receptor B-cell signaling inhibited by ibrutinib<sup><a href="#ref-42">42</a>,<a href="#ref-43">43</a></sup>. The bromodomain family of proteins are transcriptional enhancers that are required for NF-κB signaling and thus are an attractive target in MCL. Bromodomain antagonists have been shown to work synergistically with ibrutinib <i>in vitro</i> to induce apoptosis in MCL cell lines<sup><a href="#ref-44">44</a>,<a href="#ref-45">45</a></sup>. Further studies are awaited to assess whether these agents can be safely used <i>in vivo</i> alone or with ibrutinib.</p><p class="" id=d35442e1428>The recent approval of chimeric antigen receptor T-cell (CAR-T) therapy in large cell lymphoma has opened up a novel line of therapy for patients. Indeed, a phase II study of CAR-T therapy in relapsed MCL is currently underway with an identical CD19 antigen receptor (<a href="#T1">Table 1</a>). As practitioners gain more experience with the administration of these products, there will be great interest in testing their efficacy both in a relapsed setting and as part of upfront therapy versus consolidative ASCT.</p><p class="" id=d35442e1434>The male to female predominance of approximately 4:1 in MCL led a group of investigators to examine androgen receptor (AR) expression in MCL cell lines<sup><a href="#ref-46">46</a></sup>. Interestingly, compared with non-MCL cell lines, MCL cells demonstrate increased AR gene expression and elevated PSA levels consistent with active AR signaling. AR blockade with enzalutamide, an anti-androgen currently FDA approved in prostate cancer, decreased MCL cell proliferation, prompting the opening of a phase II trial to clinically investigate this effect (<a href="#T1">Table 1</a>).</p><p class="" id=d35442e1444>Further investigation into the molecularly defined subtypes of MCL has raised the possibility that the treatment might be tailored based on these results. For example, can a non-nodal <i>SOX11</i>-negative patient be managed without intensive chemotherapy induction or consolidative ASCT? Additional genetic abnormalities are still being discovered and will likely impact the risk stratification of patients and treatment strategies. For example, ataxia-telangiectasia mutated (ATM) is altered in approximately 50% of MCL cases. This protein functions as a sensor for DNA damage and, while overall it does not impact long-term survival, it may sensitize MCL cells to DNA-damaging therapy or ionizing radiation<sup><a href="#ref-47">47</a></sup>. A recent shotgun sequencing approach identified 12% of patients with NOTCH1 mutations that correlated with sensitivity of MCL cells to NOTCH inhibition <i>in vitro</i><sup><a href="#ref-48">48</a></sup>. Given the poorer prognosis of these patients, exploring drugs that target this particular mutation is appealing. TP53 mutations portend a dismal prognosis in MCL, and analysis of the TP53 cohort from the Nordic MCL2 and MCL3 trials suggests that these patients do not benefit from cytarabine-containing induction chemotherapy or ASCT<sup><a href="#ref-49">49</a></sup>. Enrichment of these patients in clinical trials using recently approved small molecule inhibitors is needed.</p><p class="" id=d35442e1465>Given the number of potential therapies on the horizon in MCL, continued patient enrollment in clinical trials is of the utmost importance. Patients who are fit and unfit for induction as well as patients with relapsed disease should be encouraged to participate, as previous MCL trials have been criticized for their bias for healthier patients<sup><a href="#ref-50">50</a></sup>. This can not only confound non-randomized phase II efficacy data but also underestimate the side effect and toxicity data of newer regimens as they are applied to a more representative population.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d35442e1475>Conclusions</h2><p class="" id=d35442e1478>The exciting developments in MCL over the past decade have begun to make substantial improvements in patient quality of life and overall survival. Ongoing long-term follow-up of the most recent clinical data will hopefully provide further evidence of durable remissions and acceptable long-term side effect profiles. We await new data incorporating our newest therapies, such as ibrutinib, with induction cytarabine chemotherapy regimens to possibly eliminate the need for upfront ASCT. The optimal duration of rituximab maintenance post-induction and whether ibrutinib maintenance is a safe and efficacious alternative to rituximab also remain unanswered. Despite these recent advances, our new therapies still fail in many patients. The continued development of targeted molecular signaling inhibitors based on the underlying biology of MCL is a therapeutic approach that will continue to yield fruitful results in this disease.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d35442e1 class=n-a></a><h2 class=main-title id=d35638>Competing interests</h2><p class=metadata-entry><a name=d35442e117 class=n-a></a><p id=d35442e118> No competing interests were disclosed.</p></p></div><div class=back-section><a name=d35442e1 class=n-a></a><h2 class=main-title id=d35640>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d35442e1485 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d35808>References</h2><div class="section ref-list"><a name=d35442e1485 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d35442e1492 class=n-a></a>Salaverria I, Royo C, Carvajal-Cuenca A, <i> et al.</i>: <i>CCND2</i> rearrangements are the most frequent genetic events in cyclin D1<sup>-</sup> mantle cell lymphoma. <i>Blood.</i> 2013; <b>121</b>(8): 1394–402. <a target=xrefwindow id=d35442e1510 href="http://www.ncbi.nlm.nih.gov/pubmed/23255553">PubMed Abstract </a> | <a target=xrefwindow id=d35442e1513 href="http://dx.doi.org/10.1182/blood-2012-08-452284">Publisher Full Text </a> | <a target=xrefwindow id=d35442e1516 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3578954">Free Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d35442e1525 class=n-a></a>Mozos A, Royo C, Hartmann E, <i> et al.</i>: SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. <i>Haematologica.</i> 2009; <b>94</b>(11): 1555–62. <a target=xrefwindow id=d35442e1536 href="http://www.ncbi.nlm.nih.gov/pubmed/19880778">PubMed Abstract </a> | <a target=xrefwindow id=d35442e1539 href="http://dx.doi.org/10.3324/haematol.2009.010264">Publisher Full Text </a> | <a target=xrefwindow id=d35442e1543 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2770966">Free Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d35442e1552 class=n-a></a>Vegliante MC, Palomero J, Pérez-Galán P, <i> et al.</i>: SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. <i>Blood.</i> 2013; <b>121</b>(12): 2175–85. <a target=xrefwindow id=d35442e1563 href="http://www.ncbi.nlm.nih.gov/pubmed/23321250">PubMed Abstract </a> | <a target=xrefwindow id=d35442e1566 href="http://dx.doi.org/10.1182/blood-2012-06-438937">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d35442e1575 class=n-a></a>Navarro A, Clot G, Royo C, <i> et al.</i>: Molecular subsets of mantle cell lymphoma defined by the <i>IGHV</i> mutational status and SOX11 expression have distinct biologic and clinical features. <i>Cancer Res.</i> 2012; <b>72</b>(20): 5307–16. <a target=xrefwindow id=d35442e1589 href="http://www.ncbi.nlm.nih.gov/pubmed/22915760">PubMed Abstract </a> | <a target=xrefwindow id=d35442e1593 href="http://dx.doi.org/10.1158/0008-5472.CAN-12-1615">Publisher Full Text </a> | <a target=xrefwindow id=d35442e1596 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3763938">Free Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731434072"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35442e1605 class=n-a></a>Abrisqueta P, Scott DW, Slack GW, <i> et al.</i>: Observation as the initial management strategy in patients with mantle cell lymphoma. <i>Ann Oncol.</i> 2017; <b>28</b>(10): 2489–95. <a target=xrefwindow id=d35442e1616 href="http://www.ncbi.nlm.nih.gov/pubmed/28961827">PubMed Abstract </a> | <a target=xrefwindow id=d35442e1619 href="http://dx.doi.org/10.1093/annonc/mdx333">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731434072">F1000 Recommendation</a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1157563"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35442e1633 class=n-a></a>Martin P, Chadburn A, Christos P, <i> et al.</i>: Outcome of deferred initial therapy in mantle-cell lymphoma. <i>J Clin Oncol.</i> 2009; <b>27</b>(8): 1209–13. <a target=xrefwindow id=d35442e1644 href="http://www.ncbi.nlm.nih.gov/pubmed/19188674">PubMed Abstract </a> | <a target=xrefwindow id=d35442e1647 href="http://dx.doi.org/10.1200/JCO.2008.19.6121">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1157563">F1000 Recommendation</a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d35442e1660 class=n-a></a>Hoster E, Klapper W, Hermine O, <i> et al.</i>: Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. <i>J Clin Oncol.</i> 2014; <b>32</b>(13): 1338–46. <a target=xrefwindow id=d35442e1671 href="http://www.ncbi.nlm.nih.gov/pubmed/24687837">PubMed Abstract </a> | <a target=xrefwindow id=d35442e1674 href="http://dx.doi.org/10.1200/JCO.2013.52.2466">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726183219"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35442e1683 class=n-a></a>Hoster E, Rosenwald A, Berger F, <i> et al.</i>: Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. <i>J Clin Oncol.</i> 2016; <b>34</b>(12): 1386–94. <a target=xrefwindow id=d35442e1694 href="http://www.ncbi.nlm.nih.gov/pubmed/26926679">PubMed Abstract </a> | <a target=xrefwindow id=d35442e1697 href="http://dx.doi.org/10.1200/JCO.2015.63.8387">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726183219">F1000 Recommendation</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732219467"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35442e1710 class=n-a></a>Aukema SM, Hoster E, Rosenwald A, <i> et al.</i>: Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. <i>Blood.</i> 2018; <b>131</b>(4): 417–20. <a target=xrefwindow id=d35442e1721 href="http://www.ncbi.nlm.nih.gov/pubmed/29196411">PubMed Abstract </a> | <a target=xrefwindow id=d35442e1724 href="http://dx.doi.org/10.1182/blood-2017-07-797019">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732219467">F1000 Recommendation</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d35442e1737 class=n-a></a>Bernard M, Gressin R, Lefrère F, <i> et al.</i>: Blastic variant of mantle cell lymphoma: A rare but highly aggressive subtype. <i>Leukemia.</i> 2001; <b>15</b>(11): 1785–91. <a target=xrefwindow id=d35442e1748 href="http://www.ncbi.nlm.nih.gov/pubmed/11681422">PubMed Abstract </a> | <a target=xrefwindow id=d35442e1751 href="http://dx.doi.org/10.1038/sj.leu.2402272">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d35442e1760 class=n-a></a>Chang JE, Carmichael LL, Kim K, <i> et al.</i>: VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study. <i>Clin Lymphoma Myeloma Leuk.</i> 2018; <b>18</b>(1): e61–e67. <a target=xrefwindow id=d35442e1771 href="http://www.ncbi.nlm.nih.gov/pubmed/29191715">PubMed Abstract </a> | <a target=xrefwindow id=d35442e1774 href="http://dx.doi.org/10.1016/j.clml.2017.10.006">Publisher Full Text </a> | <a target=xrefwindow id=d35442e1778 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5896779">Free Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d35442e1788 class=n-a></a>Chang JE, Li H, Smith MR, <i> et al.</i>: Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). <i>Blood.</i> 2014; <b>123</b>(11): 1665–73. <a target=xrefwindow id=d35442e1799 href="http://www.ncbi.nlm.nih.gov/pubmed/24458437">PubMed Abstract </a> | <a target=xrefwindow id=d35442e1802 href="http://dx.doi.org/10.1182/blood-2013-08-523845">Publisher Full Text </a> | <a target=xrefwindow id=d35442e1806 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3954048">Free Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d35442e1815 class=n-a></a>Romaguera JE, Fayad L, Rodriguez MA, <i> et al.</i>: High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. <i>J Clin Oncol.</i> 2005; <b>23</b>(28): 7013–23. <a target=xrefwindow id=d35442e1826 href="http://www.ncbi.nlm.nih.gov/pubmed/16145068">PubMed Abstract </a> | <a target=xrefwindow id=d35442e1829 href="http://dx.doi.org/10.1200/JCO.2005.01.1825">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726437194"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35442e1838 class=n-a></a>Hermine O, Hoster E, Walewski J, <i> et al.</i>: Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. <i>Lancet.</i> 2016; <b>388</b>(10044): 565–75. <a target=xrefwindow id=d35442e1849 href="http://www.ncbi.nlm.nih.gov/pubmed/27313086">PubMed Abstract </a> | <a target=xrefwindow id=d35442e1852 href="http://dx.doi.org/10.1016/S0140-6736(16)00739-X">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726437194">F1000 Recommendation</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d35442e1865 class=n-a></a>Geisler CH, Kolstad A, Laurell A, <i> et al.</i>: Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with <i>in vivo</i>-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. <i>Blood.</i> 2008; <b>112</b>(7): 2687–93. <a target=xrefwindow id=d35442e1879 href="http://www.ncbi.nlm.nih.gov/pubmed/18625886">PubMed Abstract </a> | <a target=xrefwindow id=d35442e1883 href="http://dx.doi.org/10.1182/blood-2008-03-147025">Publisher Full Text </a> | <a target=xrefwindow id=d35442e1886 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2556606">Free Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d35442e1895 class=n-a></a>Geisler CH, Kolstad A, Laurell A, <i> et al.</i>: Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. <i>Br J Haematol.</i> 2012; <b>158</b>(3): 355–62. <a target=xrefwindow id=d35442e1906 href="http://www.ncbi.nlm.nih.gov/pubmed/22640180">PubMed Abstract </a> | <a target=xrefwindow id=d35442e1909 href="http://dx.doi.org/10.1111/j.1365-2141.2012.09174.x">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d35442e1918 class=n-a></a>Dreyling M, Lenz G, Hoster E, <i> et al.</i>: Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. <i>Blood.</i> 2005; <b>105</b>(7): 2677–84. <a target=xrefwindow id=d35442e1929 href="http://www.ncbi.nlm.nih.gov/pubmed/15591112">PubMed Abstract </a> | <a target=xrefwindow id=d35442e1932 href="http://dx.doi.org/10.1182/blood-2004-10-3883">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727170548"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35442e1942 class=n-a></a>Kolstad A, Pedersen LB, Eskelund CW, <i> et al.</i>: Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years. <i>Biol Blood Marrow Transplant.</i> 2017; <b>23</b>(3): 428–35. <a target=xrefwindow id=d35442e1953 href="http://www.ncbi.nlm.nih.gov/pubmed/28039078">PubMed Abstract </a> | <a target=xrefwindow id=d35442e1956 href="http://dx.doi.org/10.1016/j.bbmt.2016.12.634">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727170548">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d35442e1969 class=n-a></a>Mei MG, Cao TM, Chen L, <i> et al.</i>: Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab. <i>Biol Blood Marrow Transplant.</i> 2017; <b>23</b>(11): 1861–9. <a target=xrefwindow id=d35442e1980 href="http://www.ncbi.nlm.nih.gov/pubmed/28733266">PubMed Abstract </a> | <a target=xrefwindow id=d35442e1983 href="http://dx.doi.org/10.1016/j.bbmt.2017.07.006">Publisher Full Text </a> | <a target=xrefwindow id=d35442e1987 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5870870">Free Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d35442e1996 class=n-a></a>Andersen NS, Pedersen LB, Laurell A, <i> et al.</i>: Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. <i>J Clin Oncol.</i> 2009; <b>27</b>(26): 4365–70. <a target=xrefwindow id=d35442e2007 href="http://www.ncbi.nlm.nih.gov/pubmed/19652064">PubMed Abstract </a> | <a target=xrefwindow id=d35442e2010 href="http://dx.doi.org/10.1200/JCO.2008.21.3116">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731386673"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35442e2019 class=n-a></a>Le Gouill S, Thieblemont C, Oberic L, <i> et al.</i>: Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. <i>N Engl J Med.</i> 2017; <b>377</b>(13): 1250–60. <a target=xrefwindow id=d35442e2030 href="http://www.ncbi.nlm.nih.gov/pubmed/28953447 ">PubMed Abstract </a> | <a target=xrefwindow id=d35442e2033 href="http://dx.doi.org/10.1056/NEJMoa1701769">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731386673">F1000 Recommendation</a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717952978"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35442e2046 class=n-a></a>Kluin-Nelemans HC, Hoster E, Hermine O, <i> et al.</i>: Treatment of older patients with mantle-cell lymphoma. <i>N Engl J Med.</i> 2012; <b>367</b>(6): 520–31. <a target=xrefwindow id=d35442e2057 href="http://www.ncbi.nlm.nih.gov/pubmed/22873532">PubMed Abstract </a> | <a target=xrefwindow id=d35442e2060 href="http://dx.doi.org/10.1056/NEJMoa1200920">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717952978">F1000 Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718297859"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35442e2073 class=n-a></a>Flinn IW, van der Jagt R, Kahl BS, <i> et al.</i>: Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. <i>Blood.</i> 2014; <b>123</b>(19): 2944–52. <a target=xrefwindow id=d35442e2084 href="http://www.ncbi.nlm.nih.gov/pubmed/24591201">PubMed Abstract </a> | <a target=xrefwindow id=d35442e2087 href="http://dx.doi.org/10.1182/blood-2013-11-531327">Publisher Full Text </a> | <a target=xrefwindow id=d35442e2091 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4260975">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718297859">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717980688"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35442e2105 class=n-a></a>Rummel MJ, Niederle N, Maschmeyer G, <i> et al.</i>: Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial. <i>Lancet.</i> 2013; <b>381</b>(9873): 1203–10. <a target=xrefwindow id=d35442e2116 href="http://www.ncbi.nlm.nih.gov/pubmed/23433739">PubMed Abstract </a> | <a target=xrefwindow id=d35442e2119 href="http://dx.doi.org/10.1016/S0140-6736(12)61763-2">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717980688">F1000 Recommendation</a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d35442e2132 class=n-a></a>Gressin R, Callanan M, Daguindau N, <i> et al.</i>: Frontline Therapy with the Ribvd Regimen Elicits High Clinical and Molecular Response Rates and Long PFS in Elderly Patients Mantle Cell Lymphoma (MCL); Final Results of a Prospective Phase II Trial By the Lysa Group. <i>Blood.</i> 2014; <b>124</b>(21): 148. <a target=xrefwindow id=d35442e2143 href="http://www.bloodjournal.org/content/124/21/148">Reference Source</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727087385"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35442e2152 class=n-a></a>Visco C, Chiappella A, Nassi L, <i> et al.</i>: Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. <i>Lancet Haematol.</i> 2017; <b>4</b>(1): e15–e23. <a target=xrefwindow id=d35442e2163 href="http://www.ncbi.nlm.nih.gov/pubmed/27927586">PubMed Abstract </a> | <a target=xrefwindow id=d35442e2166 href="http://dx.doi.org/10.1016/S2352-3026(16)30185-5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727087385">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d35442e2179 class=n-a></a>Ruan J, Martin P, Shah B, <i> et al.</i>: Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma. <i>N Engl J Med.</i> 2015; <b>373</b>(19): 1835–44. <a target=xrefwindow id=d35442e2190 href="http://www.ncbi.nlm.nih.gov/pubmed/26535512">PubMed Abstract </a> | <a target=xrefwindow id=d35442e2193 href="http://dx.doi.org/10.1056/NEJMoa1505237">Publisher Full Text </a> | <a target=xrefwindow id=d35442e2197 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4710541">Free Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726470562"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35442e2206 class=n-a></a>Albertsson-Lindblad A, Kolstad A, Laurell A, <i> et al.</i>: Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma. <i>Blood.</i> 2016; <b>128</b>(14): 1814–20. <a target=xrefwindow id=d35442e2217 href="http://www.ncbi.nlm.nih.gov/pubmed/27354719">PubMed Abstract </a> | <a target=xrefwindow id=d35442e2220 href="http://dx.doi.org/10.1182/blood-2016-03-704023">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726470562">F1000 Recommendation</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d35442e2233 class=n-a></a>Robak T, Huang H, Jin J, <i> et al.</i>: Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. <i>N Engl J Med.</i> 2015; <b>372</b>(10): 944–53. <a target=xrefwindow id=d35442e2244 href="http://www.ncbi.nlm.nih.gov/pubmed/25738670">PubMed Abstract </a> | <a target=xrefwindow id=d35442e2247 href="http://dx.doi.org/10.1056/NEJMoa1412096">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d35442e2257 class=n-a></a>Fisher RI, Bernstein SH, Kahl BS, <i> et al.</i>: Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. <i>J Clin Oncol.</i> 2006; <b>24</b>(30): 4867–74. <a target=xrefwindow id=d35442e2268 href="http://www.ncbi.nlm.nih.gov/pubmed/17001068">PubMed Abstract </a> | <a target=xrefwindow id=d35442e2271 href="http://dx.doi.org/10.1200/JCO.2006.07.9665">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d35442e2280 class=n-a></a>Goy A, Kalayoglu Besisik S, Drach J, <i> et al.</i>: Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial. <i>Br J Haematol.</i> 2015; <b>170</b>(4): 496–503. <a target=xrefwindow id=d35442e2291 href="http://www.ncbi.nlm.nih.gov/pubmed/25921098">PubMed Abstract </a> | <a target=xrefwindow id=d35442e2294 href="http://dx.doi.org/10.1111/bjh.13456">Publisher Full Text </a> | <a target=xrefwindow id=d35442e2298 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5029780">Free Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718021375"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35442e2307 class=n-a></a>Wang ML, Rule S, Martin P, <i> et al.</i>: Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. <i>N Engl J Med.</i> 2013; <b>369</b>(6): 507–16. <a target=xrefwindow id=d35442e2318 href="http://www.ncbi.nlm.nih.gov/pubmed/23782157">PubMed Abstract </a> | <a target=xrefwindow id=d35442e2321 href="http://dx.doi.org/10.1056/NEJMoa1306220">Publisher Full Text </a> | <a target=xrefwindow id=d35442e2325 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4513941">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718021375">F1000 Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726019266"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35442e2338 class=n-a></a>Dreyling M, Jurczak W, Jerkeman M, <i> et al.</i>: Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. <i>Lancet.</i> 2016; <b>387</b>(10020): 770–8. <a target=xrefwindow id=d35442e2349 href="http://www.ncbi.nlm.nih.gov/pubmed/26673811">PubMed Abstract </a> | <a target=xrefwindow id=d35442e2352 href="http://dx.doi.org/10.1016/S0140-6736(15)00667-4">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726019266">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d35442e2365 class=n-a></a>Hess G, Herbrecht R, Romaguera J, <i> et al.</i>: Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. <i>J Clin Oncol.</i> 2009; <b>27</b>(23): 3822–9. <a target=xrefwindow id=d35442e2376 href="http://www.ncbi.nlm.nih.gov/pubmed/19581539">PubMed Abstract </a> | <a target=xrefwindow id=d35442e2379 href="http://dx.doi.org/10.1200/JCO.2008.20.7977">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d35442e2388 class=n-a></a>Goy A, Sinha R, Williams ME, <i> et al.</i>: Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. <i>J Clin Oncol.</i> 2013; <b>31</b>(29): 3688–95. <a target=xrefwindow id=d35442e2399 href="http://www.ncbi.nlm.nih.gov/pubmed/24002500">PubMed Abstract </a> | <a target=xrefwindow id=d35442e2402 href="http://dx.doi.org/10.1200/JCO.2013.49.2835">Publisher Full Text </a> | <a target=xrefwindow id=d35442e2406 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4879693">Free Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726166547"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35442e2416 class=n-a></a>Trněný M, Lamy T, Walewski J, <i> et al.</i>: Lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): A phase 2, randomised, multicentre trial. <i>Lancet Oncol.</i> 2016; <b>17</b>(3): 319–31. <a target=xrefwindow id=d35442e2427 href="http://www.ncbi.nlm.nih.gov/pubmed/26899778">PubMed Abstract </a> | <a target=xrefwindow id=d35442e2430 href="http://dx.doi.org/10.1016/S1470-2045(15)00559-8">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726166547">F1000 Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732304846"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35442e2443 class=n-a></a>Wang M, Rule S, Zinzani PL, <i> et al.</i>: Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. <i>Lancet.</i> 2018; <b>391</b>(10121): 659–67. <a target=xrefwindow id=d35442e2454 href="http://www.ncbi.nlm.nih.gov/pubmed/29241979">PubMed Abstract </a> | <a target=xrefwindow id=d35442e2457 href="http://dx.doi.org/10.1016/S0140-6736(17)33108-2">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732304846">F1000 Recommendation</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732915796"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35442e2470 class=n-a></a>Tam CS, Anderson MA, Pott C, <i> et al.</i>: Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. <i>N Engl J Med.</i> 2018; <b>378</b>(13): 1211–23. <a target=xrefwindow id=d35442e2481 href="http://www.ncbi.nlm.nih.gov/pubmed/29590547">PubMed Abstract </a> | <a target=xrefwindow id=d35442e2484 href="http://dx.doi.org/10.1056/NEJMoa1715519">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732915796">F1000 Recommendation</a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d35442e2497 class=n-a></a>Davids MS, Roberts AW, Seymour JF, <i> et al.</i>: Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. <i>J Clin Oncol.</i> 2017; <b>35</b>(8): 826–33. <a target=xrefwindow id=d35442e2508 href="http://www.ncbi.nlm.nih.gov/pubmed/28095146">PubMed Abstract </a> | <a target=xrefwindow id=d35442e2511 href="http://dx.doi.org/10.1200/JCO.2016.70.4320">Publisher Full Text </a> | <a target=xrefwindow id=d35442e2515 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5455685">Free Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d35442e2524 class=n-a></a>Krüger WH, Hirt C, Basara N, <i> et al.</i>: Allogeneic stem cell transplantation for mantle cell lymphoma--final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO). <i>Ann Hematol.</i> 2014; <b>93</b>(9): 1587–97. <a target=xrefwindow id=d35442e2535 href="http://www.ncbi.nlm.nih.gov/pubmed/24782119">PubMed Abstract </a> | <a target=xrefwindow id=d35442e2538 href="http://dx.doi.org/10.1007/s00277-014-2087-z">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d35442e2547 class=n-a></a>Tessoulin B, Ceballos P, Chevallier P, <i> et al.</i>: Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC. <i>Bone Marrow Transplant.</i> 2016; <b>51</b>(9): 1184–90. <a target=xrefwindow id=d35442e2558 href="http://www.ncbi.nlm.nih.gov/pubmed/27111043">PubMed Abstract </a> | <a target=xrefwindow id=d35442e2561 href="http://dx.doi.org/10.1038/bmt.2016.102">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718215363"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35442e2571 class=n-a></a>Rahal R, Frick M, Romero R, <i> et al.</i>: Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma. <i>Nat Med.</i> 2014; <b>20</b>(1): 87–92. <a target=xrefwindow id=d35442e2582 href="http://www.ncbi.nlm.nih.gov/pubmed/24362935">PubMed Abstract </a> | <a target=xrefwindow id=d35442e2585 href="http://dx.doi.org/10.1038/nm.3435">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718215363">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726321558"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35442e2598 class=n-a></a>Saba NS, Liu D, Herman SE, <i> et al.</i>: Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma. <i>Blood.</i> 2016; <b>128</b>(1): 82–92. <a target=xrefwindow id=d35442e2609 href="http://www.ncbi.nlm.nih.gov/pubmed/27127301">PubMed Abstract </a> | <a target=xrefwindow id=d35442e2612 href="http://dx.doi.org/10.1182/blood-2015-11-681460">Publisher Full Text </a> | <a target=xrefwindow id=d35442e2616 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4937360">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726321558">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d35442e2629 class=n-a></a>Sun B, Fiskus W, Qian Y, <i> et al.</i>: BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells. <i>Leukemia.</i> 2018; <b>32</b>(2): 343–52. <a target=xrefwindow id=d35442e2640 href="http://www.ncbi.nlm.nih.gov/pubmed/28663582">PubMed Abstract </a> | <a target=xrefwindow id=d35442e2643 href="http://dx.doi.org/10.1038/leu.2017.207">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d35442e2652 class=n-a></a>Sun B, Shah B, Fiskus W, <i> et al.</i>: Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. <i>Blood.</i> 2015; <b>126</b>(13): 1565–74. <a target=xrefwindow id=d35442e2663 href="http://www.ncbi.nlm.nih.gov/pubmed/26254443">PubMed Abstract </a> | <a target=xrefwindow id=d35442e2666 href="http://dx.doi.org/10.1182/blood-2015-04-639542">Publisher Full Text </a> | <a target=xrefwindow id=d35442e2670 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4582333">Free Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d35442e2679 class=n-a></a>Mostaghel EA, Martin PS, Mongovin S, <i> et al.</i>: Androgen receptor expression in mantle cell lymphoma: Potential novel therapeutic implications. <i>Exp Hematol.</i> 2017; <b>49</b>: 34–38.e2. <a target=xrefwindow id=d35442e2690 href="http://www.ncbi.nlm.nih.gov/pubmed/28115200">PubMed Abstract </a> | <a target=xrefwindow id=d35442e2693 href="http://dx.doi.org/10.1016/j.exphem.2017.01.001">Publisher Full Text </a> | <a target=xrefwindow id=d35442e2697 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5393923">Free Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727002465"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35442e2706 class=n-a></a>Ahmed M, Li L, Pinnix C, <i> et al.</i>: ATM mutation and radiosensitivity: An opportunity in the therapy of mantle cell lymphoma. <i>Crit Rev Oncol Hematol.</i> 2016; <b>107</b>: 14–9. <a target=xrefwindow id=d35442e2717 href="http://www.ncbi.nlm.nih.gov/pubmed/27823642">PubMed Abstract </a> | <a target=xrefwindow id=d35442e2720 href="http://dx.doi.org/10.1016/j.critrevonc.2016.08.008">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727002465">F1000 Recommendation</a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d35442e2734 class=n-a></a>Kridel R, Meissner B, Rogic S, <i> et al.</i>: Whole transcriptome sequencing reveals recurrent <i>NOTCH1</i> mutations in mantle cell lymphoma. <i>Blood.</i> 2012; <b>119</b>(9): 1963–71. <a target=xrefwindow id=d35442e2748 href="http://www.ncbi.nlm.nih.gov/pubmed/22210878">PubMed Abstract </a> | <a target=xrefwindow id=d35442e2752 href="http://dx.doi.org/10.1182/blood-2011-11-391474">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/728772345"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35442e2761 class=n-a></a>Eskelund CW, Dahl C, Hansen JW, <i> et al.</i>: <i>TP53</i> mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. <i>Blood.</i> 2017; <b>130</b>(17): 1903–10. <a target=xrefwindow id=d35442e2775 href="http://www.ncbi.nlm.nih.gov/pubmed/28819011">PubMed Abstract </a> | <a target=xrefwindow id=d35442e2779 href="http://dx.doi.org/10.1182/blood-2017-04-779736">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/728772345">F1000 Recommendation</a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d35442e2792 class=n-a></a>Augustin A, Le Gouill S, Gressin R, <i> et al.</i>: Survival benefit of mantle cell lymphoma patients enrolled in clinical trials; a joint study from the LYSA group and French cancer registries. <i>J Cancer Res Clin Oncol.</i> 2018; <b>144</b>(4): 629–35. <a target=xrefwindow id=d35442e2803 href="http://www.ncbi.nlm.nih.gov/pubmed/29022078">PubMed Abstract </a> | <a target=xrefwindow id=d35442e2806 href="http://dx.doi.org/10.1007/s00432-017-2529-9">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 25 Jul 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-1136/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-1136/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA<br/> <p> <div class=margin-bottom> Michael Schieber <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Leo I. Gordon <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Reem Karmali <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/7-1136/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 25 Jul 2018, 7:1136 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.14122.1">https://doi.org/10.12688/f1000research.14122.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2018 Schieber M <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=15360 data-id=14122 data-downloads="" data-views="" data-scholar="10.12688/f1000research.14122.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/7-1136/v1/pdf?article_uuid=335ffc0e-e637-4313-8181-fc476dba01bf" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.14122.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Schieber M, Gordon LI and Karmali R. Current overview and treatment of mantle cell lymphoma [version 1; peer review: 3 approved] <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1136 (<a href="https://doi.org/10.12688/f1000research.14122.1" target=_blank>https://doi.org/10.12688/f1000research.14122.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=14122 id=mobile-track-article-signin-14122 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/14122?target=/articles/7-1136/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=15360 /> <input name=articleId type=hidden value=14122 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Vincent Ribrag</strong>, Chairman of DITEP multidisciplinary committee and Chief of Molecular therapeutics in hematological early drug development, Gustave Roussy Comprehensive Cancer Center, France </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Jonathon B. Cohen</strong>, Winship Cancer Institute, Emory University, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Andre H. Goy</strong>, Lymphoma Division, John Theurer Cancer Center, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 25 Jul 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-1136/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-1136/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=36724-36191></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=36725-36190></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=36714-36189></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/7-1136/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>25 Jul 18</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Vincent Ribrag</strong>, Chairman of DITEP multidisciplinary committee and Chief of Molecular therapeutics in hematological early drug development, Gustave Roussy Comprehensive Cancer Center, France </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Jonathon B. Cohen</strong>, Winship Cancer Institute, Emory University, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Andre H. Goy</strong>, Lymphoma Division, John Theurer Cancer Center, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/7-1136/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/7-1136/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Current overview and treatment of mantle...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/7-1136/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/7-1136/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/7-1136/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Schieber M et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/7-1136/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/7-1136",
            templates : {
                twitter : "Current overview and treatment of mantle cell lymphoma. Schieber M et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/7-1136/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Current overview and treatment of mantle cell lymphoma", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Current overview and treatment of mantle cell lymphoma", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/14122/15360")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "15360");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "36189": 0,
                           "36190": 0,
                           "36191": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "00ba4f86-00dd-49f3-aa4d-77158d6c2132";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1136.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1136.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1136.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/7-1136.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/7-1136.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>